Overview

Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer

Status:
Unknown status

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

Stage 1:First line therapy Sequential therapy of S1+Docetaxel followed by S1 is superior to concomitant S1+Docetaxel in the safety and clinical efficiency. Stage 2:Second line therapy To explore the feasibility of single drug(S1) maintenance treatment for advanced gastric cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Hebei Tumor Hospital

Treatments:

Docetaxel